Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Operations (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Cash from Operations for 6 consecutive years, with 28542000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 70.65% to 28542000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 82235000.0, a 87.69% decrease, with the full-year FY2025 number at 82235000.0, down 87.69% from a year prior.
  • Cash from Operations was 28542000.0 for Q4 2025 at Janux Therapeutics, down from 12856000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5563000.0 in Q1 2021 to a low of 28542000.0 in Q4 2025.
  • A 5-year average of 11826100.0 and a median of 11811000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 543.4% in 2021, then surged 80.95% in 2024.
  • Janux Therapeutics' Cash from Operations stood at 10481000.0 in 2021, then decreased by 13.66% to 11913000.0 in 2022, then increased by 16.89% to 9901000.0 in 2023, then tumbled by 68.92% to 16725000.0 in 2024, then plummeted by 70.65% to 28542000.0 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Cash from Operations are 28542000.0 (Q4 2025), 12856000.0 (Q3 2025), and 23813000.0 (Q2 2025).